Bora Pharmaceuticals To Acquire GSK Mfg Facility in Canada
Bora Pharmaceuticals, a CDMO of non-sterile oral solid dosage forms, has agreed to acquire a GlaxoSmithKline’s (GSK) manufacturing facility in Mississauga, Ontario, Canada.
The GSK facility produces approximately 50 different products for over 100 markets worldwide and employs approximately 400 manufacturing staff, who will be invited to join Bora Pharmaceuticals as part of the transaction. Bora Pharmaceuticals will continue to manufacture, under contract, the existing GSK product line for a minimum of five years. GSK employees in the company’s Pharmaceuticals and Consumer Healthcare commercial businesses, who currently work in office space at the Mississauga site, will move to new locations within an agreed time frame following the close of the transaction.
Subject to the appropriate regulatory clearances, the transaction will see the ownership of the entire GSK Mississauga site, including all facilities, transfer over to Bora Pharmaceuticals. The transaction is expected to be completed no later than the end of 2020.
Bora Pharmaceuticals specializes in modified-release manufacturing and solvent processing for non-sterile oral solid dosage forms. It currently employs more than 475 people across two facilities in Taiwan.